4pzz
From Proteopedia
(Difference between revisions)
m (Protected "4pzz" [edit=sysop:move=sysop]) |
|||
| (7 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Second-site screening of K-Ras in the presence of covalently attached first-site ligands== | |
| + | <StructureSection load='4pzz' size='340' side='right'caption='[[4pzz]], [[Resolution|resolution]] 1.40Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4pzz]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PZZ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PZZ FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.403Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2XO:1H-BENZIMIDAZOL-2-YLMETHANETHIOL'>2XO</scene>, <scene name='pdbligand=GDP:GUANOSINE-5-DIPHOSPHATE'>GDP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4pzz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4pzz OCA], [https://pdbe.org/4pzz PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4pzz RCSB], [https://www.ebi.ac.uk/pdbsum/4pzz PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4pzz ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | K-Ras is a well-validated cancer target but is considered to be "undruggable" due to the lack of suitable binding pockets. We previously discovered small molecules that bind weakly to K-Ras but wanted to improve their binding affinities by identifying ligands that bind near our initial hits that we could link together. Here we describe an approach for identifying second site ligands that uses a cysteine residue to covalently attach a compound for tight binding to the first site pocket followed by a fragment screen for binding to a second site. This approach could be very useful for targeting Ras and other challenging drug targets. | ||
| - | + | A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.,Sun Q, Phan J, Friberg AR, Camper DV, Olejniczak ET, Fesik SW J Biomol NMR. 2014 Sep;60(1):11-4. doi: 10.1007/s10858-014-9849-8. Epub 2014 Aug , 3. PMID:25087006<ref>PMID:25087006</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| + | </div> | ||
| + | <div class="pdbe-citations 4pzz" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[GTPase KRas 3D structures|GTPase KRas 3D structures]] | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Camper DV]] | ||
| + | [[Category: Fesik SW]] | ||
| + | [[Category: Friberg A]] | ||
| + | [[Category: Olejniczak ET]] | ||
| + | [[Category: Phan J]] | ||
| + | [[Category: Sun Q]] | ||
Current revision
Second-site screening of K-Ras in the presence of covalently attached first-site ligands
| |||||||||||
Categories: Homo sapiens | Large Structures | Camper DV | Fesik SW | Friberg A | Olejniczak ET | Phan J | Sun Q
